Our Team
Executive Management
Dr. Markus Mandler
Founder & CEO
Dr. Mandler is the former CSO of Accanis Biotech. Prior to that he served as head of the Neurodegeneration Department at AFFiRiS AG where he was developing the vaccine portfolio for the treatment of neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and multisystem atrophy. He was responsible for preclinical development of the first two peptide-based vaccines ever tested in humans for Parkinson's disease and multisystem atrophy. He has authored 20 publications in high impact journals and more than 25 patents and patent applications and has received multiple national and international research grants for his work.
Dr. Sabine Schmidhuber
Principal Scientist & Project Leader
Dr. Schmidhuber was project leader at Accanis Biotech as well as project leader for late preclinical vaccine development in the Neurodegeneration Department of AFFiRiS AG, focusing on methods for evaluating the efficacy of vaccines in Parkinson’s disease. She received her PhD from Paracelsus Medical Private University (Salzburg, Austria) and Kings College in London (UK) and completed her post-doc at the Saban Research Institute of Children's Hospital Los Angeles and PMU Salzburg, focusing on inflammation and innate immunity.
Dr. Achim Schneeberger
Founder & CMO
Prominent leader in dermatology and vaccine research. At Tridem he drives the company's R&D and clinical development strategy and oversees its funding and infrastructure. From 2016 to 2021, he was the CMO at ACCANIS, leading the Eurostars-2 project on scar repair and engaging with KOLs. Previously, at AFFiRiS AG (2006–2016), he built the clinical department and managed pivotal studies (n=18) in chronic diseases including AD and PD. He served as PI of the MJFF grant supporting early clinical development of PD01A, the first aSyn targeting vaccine ever tested in humans. At ADVANTAGE and LAXXON, in addition to managing non-clinical development he was responsible for quality and manufacturing portfolios. Dr. Schneeberger has secured notable research grants and authored over 50 publications and 20 patents.
Dr. Thomas Schaffer
Financial Advisor
Financial advisor to Tridem Bioscience. Previously, he was the CFO and a Management Board Member at Biofrontera AG, a biotech company in dermatology, from 2013 to 2021, bringing significant expertise in the pharma business area.
Advisory Board
Prof. Dr. Brit Mollenhauer
Neurologist and global Parkinson KOL, focus biomarker development, diagnosis, development and application of novel treatment strategies for Parkinson’s disease.
Univ.Prof. PD Dr. Stefan Wöhrl
Renowned Dermatologist, Allergologist and Global KOL for Allergy and Immunotherapy.
Prof. Dr. Richard Weiss
Biochemist, immunologist and international KOL for gluconeoconjugate vaccines.
Dr. Ulrich Granzer
Founder of Granzer Regulatory Consulting & Services with long-standing experience in all regulatory aspects of the pharmaceutical industry (marketing authorisations: centralized and decentralized EU procedures, US IND and NDA procedures at CBER and CBER with >150 procedures in total).
